Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real-World Cohort Study

This real-world cohort study assessed the efficacy and safety of baricitinib in 47 Chinese patients with alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU). The study found that 78.7% of patients achieved significant hair regrowth, with a mean onset time of 6.04 weeks, and 34% experienced complete regrowth. Eyebrow and eyelash regrowth occurred in over 85% of patients. Baricitinib was well-tolerated, with mild side effects and no severe adverse events. Patients with a disease duration of 4 years or less showed greater improvement. The study suggests baricitinib as an effective treatment for AA, with higher response rates than previous trials, and emphasizes the importance of early intervention and long-term maintenance therapy. Limitations include the small sample size and retrospective design, indicating a need for further research.